ED
FSTX

Exane Derivatives’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Exane Derivatives’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,400
Closed -$120K – 777
2020
Q2 		$120K Hold
20,400
– – 0.03% 271
2020
Q1 		$75.9K Buy
+20,400
New +$106K 0.02% 316

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

Exane Derivatives's FSTX Position: Q3 2020 in Review

Exane Derivatives sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q3 2020, closing a stake of 20,400 shares — an estimated $120K sold.

Exane Derivatives first reported a position in FSTX in Q1 2020 and held it in 2 quarters. The position peaked at $120K in Q2 2020. 23 funds tracked by Wall St. Rank hold FSTX as of Q3 2020.

  • Exane Derivatives reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Exane Derivatives sold 20,400 F-star Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $120K.
  • Exane Derivatives first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2020 and held it in 2 quarters.
  • Exane Derivatives's F-star Therapeutics, Inc. Common Stock position peaked at $120K in Q2 2020.
  • 23 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Exane Derivatives's 13F filing for Q3 2020, filed 6 Oct 2020.